Co-Diagnostics CFO exits; Bohrer takes finance helm

Co-Diagnostics, Inc. (CODX) reported that Chief Financial Officer Brian Brown’s employment ended on September 2, 2026, which was his last day serving as the company’s principal financial officer and principal accounting officer.

Rhea-AI Filing Summary

Co-Diagnostics, Inc. (CODX) reported that Chief Financial Officer Brian Brown’s employment ended on September 2, 2026, which was his last day serving as the company’s principal financial officer and principal accounting officer. On the same date, Daniel Bohrer, Executive Vice President of Finance and Accounting, was designated as the new principal financial officer and principal accounting officer.

In connection with this appointment, Mr. Bohrer’s annual salary increased from $225,000 to $255,000. The company notes that Mr. Bohrer, age 49, has extensive prior experience in finance, accounting, and audit roles at Co-Diagnostics, Workfront, Inc., and EY, and that he has no family relationships, related person transactions, or selection arrangements with other company insiders.

Positive

• None.

Negative

• CFO departure: Chief Financial Officer Brian Brown’s employment ended on September 2, 2026, resulting in a change in the company’s principal financial officer and principal accounting officer roles.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date of CFO departure: September 2, 2026 New principal officer annual salary: $255,000 Previous annual salary: $225,000 +2 more

5 metrics

Effective date of CFO departure September 2, 2026 Brian Brown’s last day of employment and service as principal financial and accounting officer

New principal officer annual salary $255,000 Annual salary for Daniel Bohrer after designation as principal financial and accounting officer

Previous annual salary $225,000 Annual salary for Daniel Bohrer before his new designation

New principal officer age 49 Age of Daniel Bohrer as disclosed in the filing

Tenure as VP of Finance and Accounting September 2021 to September 2026 Period during which Daniel Bohrer served as Vice President of Finance and Accounting at Co-Diagnostics

Key Terms

principal financial officer, principal accounting officer, equity compensation plan, related person transaction, +1 more

5 terms

principal financial officer financial

"served as the Company’s principal financial officer and principal accounting officer"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

principal accounting officer financial

"will serve as the Company’s principal financial officer and principal accounting officer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

equity compensation plan financial

"administering the Company’s equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

related person transaction regulatory

"is not a party to any related person transaction with the Company"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What leadership change did Co-Diagnostics, Inc. (CODX) announce on September 2, 2026?

Co-Diagnostics, Inc. stated that its Chief Financial Officer, Brian Brown, ended his employment on September 2, 2026, which was his last day serving as principal financial officer and principal accounting officer. Daniel Bohrer was designated to assume both principal roles effective the same date.

Who is now the principal financial officer of Co-Diagnostics, Inc. (CODX)?

Effective September 2, 2026, Daniel Bohrer, Executive Vice President of Finance and Accounting, serves as Co-Diagnostics’ principal financial officer and principal accounting officer, succeeding Brian Brown in those roles.

How did Co-Diagnostics, Inc. (CODX) change Daniel Bohrer’s compensation?

In connection with Daniel Bohrer’s designation as principal financial officer and principal accounting officer, Co-Diagnostics increased his annual salary from $225,000 to $255,000.

What experience does Daniel Bohrer have before becoming principal financial officer at CODX?

Daniel Bohrer, age 49, became Executive Vice President of Finance and Accounting in September 2026 and previously served as Vice President of Finance and Accounting from September 2021 to September 2026, following roles at Workfront, Inc. and EY in accounting, reporting, and audit.

Does Co-Diagnostics, Inc. (CODX) report any related person transactions involving Daniel Bohrer?

Co-Diagnostics states that Daniel Bohrer is not a party to any related person transaction with the company, has no family relationship with any director or executive officer, and has no arrangements or understandings with any person pursuant to which he was selected as an officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:31 PM Accepted by SEC EDGAR 09/04/2026 - 04:30 PM Learn about SEC filing dates

false 0001692415 0001692415 2026-09-02 2026-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2026

CO-DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Utah		001-38148		46-2609363
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No. )

2401 S. Foothill Drive, Suite D, Salt Lake City Utah 84109

(Address of principal executive offices) (Zip Code)

(801) 438-1036

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CODX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 2, 2026, Co-Diagnostics, Inc. (the “Company”) and Brian Brown, the Company’s Chief Financial Officer, determined that Mr. Brown’s last day of employment with the Company would be September 2, 2026 (the “Separation Date”). Mr. Brown served as the Company’s principal financial officer and principal accounting officer through the Separation Date.

Effective as of the Separation Date, Daniel Bohrer, the Company’s Executive Vice President of Finance and Accounting, will serve as the Company’s principal financial officer and principal accounting officer. In connection with such appointment, Mr. Bohrer’s annual salary was increased from $225,000 to $255,000.

Mr. Bohrer, age 49, became the Company’s Executive Vice President of Finance and Accounting in September 2026. From September 2021 to September 2026, Mr. Bohrer served as the Company’s Vice President of Finance and Accounting where his duties included overseeing the Company’s accounting department, directing the preparation of financial statements, footnotes and audit support schedules, preparing the Company’s annual, quarterly and current reports with the SEC, managing all aspects of the Company’s annual audit, and administering the Company’s equity compensation plan. From October 2016 through September 2021, Mr. Bohrer served as the Director of Accounting for Workfront, Inc. (acquired by Adobe, Inc. in 2020), a Utah-based software company providing cloud-based work and project management software, where he was responsible for internal and external financial accounting and reporting, technical accounting leadership, equity compensation plan administration, and treasury functions including debt compliance reporting and cash forecasting. From January 2014 through October 2016, Mr. Bohrer served as an Assurance Senior Manager at EY, where he provided audit services to various clients in multiple industries. Mr. Bohrer holds a Master of Business Administration and Bachelor of Science in Accounting from Utah State University and is a licensed CPA in the State of Utah.

Mr. Bohrer (i) has no family relationship with any director or other executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer, (ii) is not a party to any related person transaction with the Company, and (iii) has no arrangements or understandings with any other person pursuant to which he was selected as an officer of the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	CO-DIAGNOSTICS, INC.
Date: September 4, 2026	By:	/s/ Dwight Egan
	Name:	Dwight Egan
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB